Products for Research Use Only
RegisterLogin

KMI169

CAT: 0804-HY-157486-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-157486-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
KMI169 is a potent and selective inhibitor targeting lysine methyl-transferase (KMT9) (IC50 = 0.05 μM, Kd = 0.025 μM) . KMI169 functions as a bi-substrate inhibitor targeting the cofactor S-5’-adenosyl-L-methionine (SAM) and substrate binding pockets of KMT9. KMI169 can downregulate target genes involved in cell cycle regulation and impair proliferation of tumor cells by inhibiting KMT9. KMI169 is a valuable tool to probe cellular KMT9 functions and can be research for combating diseases including prostate, lung, colon, and invasive bladder cancer[1][2].
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/kmi169.html
Purity
98.00
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC1=C2C(C3=NN(C=C3Cl)CC4=CC=CC=C4)=CN([C@@H]5C[C@H](C6=CC(CN7CCC7)=CC=C6)[C@@H](O)[C@H]5O)C2=NC(Cl)=N1
Molecular Formula
C31H31Cl2N7O2
Molecular Weight
604.53
References & Citations
[1]Wang S, et al. Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity. Nat Commun. 2024 Jan 2;15 (1) :43.|[2]Totonji, S., et., (2024) . Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer. Cancers, 16 (8), 1532.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-P990278Anti-Mouse CD29 Antibody (KMI6)

Alternative Products

CatalogName
GTR19261650-01KMI169
A24394-100KMI169 100mg
A24394-50KMI169 50mg
A24394-10KMI169 10mg
A24394-5KMI169 5mg

Popular Products